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Abstract
Objective
To assess the sleep quality in primary Sjögren’s syndrome (pSS) patients and evaluate its relationship with the disease, 
quality of life and mood disorders.
Methods
The sleep quality of 29 pSS women and 29 matched controls was assessed by the Pittsburgh Sleep Quality Index (PSQI). 
Seven domains are grouped according to three factors: F1 perceived sleep quality (subjective sleep quality, sleep latency, 
use of sleeping medication), F2 sleep efficiency (sleep duration, habitual sleep efficiency) and F3 daily disturbances (sleep 
disturbances, daytime dysfunction). These domains are scored as a single factor of global sleep quality. The Short Form 
Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale and Hospital Anxiety and 
Depression Scale (HADS) were also administered. Disease activity and damage were evaluated with the EULAR Sjögren’s 
syndrome disease activity index (ESSDAI), the Sjögren’s Syndrome Disease Activity and Damage Indexes (SSDAI, SSDDI). 
Results
The mean PSQI global score had higher pathological values  (8.6±4.6) compared with controls (5.6±2.2) (p=0.002). 
F1 and F3 were significantly worse in cases (p=0.01, p=0.009). A negative correlation was found between SF-36 
subscales and the global PSQI, F2 and F3. The anxiety HADS correlated with F2 and F3, while depression only with F3. 
No correlation with FACIT and disease indexes emerged.
Conclusion
Using PSQI, an impaired sleep quality was demonstrated in pSS patients, especially with perceived quality and the daily 
disturbances. It is associated with a reduced quality of life but not with disease-related variables. 
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Introduction
Primary Sjögren’s syndrome (pSS) is 
an autoimmune disease characterised 
by lacrimal and salivary gland involve-
ment, resulting in a loss of their func-
tion. Even though sicca symptoms are 
the most frequent features of the dis-
ease, the inflammatory process can ex-
tend to several other organs and tissues 
and constitutional symptoms, including 
fatigue, weight loss, fever, and wide-
spread pain, may impair  quality of life. 
Sleep disturbances, excessive day-
time sleepiness and fatigue have been 
described in patients with pSS (1-4) 
alongside a wide spectrum of reasons: 
the possible overlap between pSS and 
fibromyalgia (5-6), mood disorders (7, 
8), muscle and joint pain, night sleep re-
striction linked to the necessity to awake 
to drink water for sicca symptoms (9), 
restless legs symptoms and a concomi-
tant obstructive sleep apnea syndrome 
(OSAS), which have been reported with 
a higher prevalence in pSS patients (10). 
It is not clear whether sleep disturbances 
in pSS may be related to disease activity 
or to the damage linked to the disease 
itself. In fact, no standardised tool for 
measuring disease activity and damage 
was available for pSS until the recent 
publication of the SS Disease Activity 
Index (SSDAI), the SS disease damage 
index (SSDDI) (11) and the EULAR SS 
Disease Activity Index (ESSDAI) (12). 
On the contrary, measuring sleep qual-
ity is an area of intensive research and 
several patient reported outcome instru-
ments are available to measure different 
aspects of sleep dysfunction (13). The 
Pittsburgh  Sleep Quality Index (PSQI) 
has been widely used (14-22) and has 
robust reliability (23, 15, 16), validity 
(23, 15, 17), responsiveness and inter-
pretability (23). This tool has been suc-
cessfully used in several rheumatic dis-
orders (24-28).
Given that many different variables 
seem to influence sleep quality, and the 
paucity of data regarding this topic in 
pSS, the objectives of this study were: 1) 
to characterise sleep quality using PSQI 
in pSS patients compared to the general 
population; and 2) to assess the possible 
correlation between sleep disturbances 
and disease activity and damage, consti-
tutional symptoms and mood disorders. 
Patients and methods
Patients and outcome measures
Thirty-one female out-patients, with 
an established diagnosis of pSS ac-
cording to the American-European 
Consensus group criteria (29), were 
consecutively enrolled during routine 
follow-up visits at the Sjögren’s Syn-
drome Clinic, at the Sapienza Uni-
versity of Rome with the approval of 
the local ethics committee and after 
informed written consent. At the time 
of enrollment, demographic, clinical 
and laboratory data were collected 
and disease activity and damage were 
scored using validated scales (SSDAI-
Sjögren’s Syndrome Disease Activ-
ity Index, SSDDI-Sjögren’s Syndrome 
Disease Damage Index, ESSDAI-
EULAR Sjögren’s Syndrome Disease 
Activity Index) (11, 12). Schirmer’s 
test and sialometry values were used 
for an objective evaluation of dryness 
symptoms; they were considered path-
ological when lower than 5 mm/5 min 
and 1.5 ml/15 min, respectively. More-
over, the Italian validated versions of 
the Short Form Health Survey (SF-36)
(30), the Functional Assessment of 
Chronic Illness Therapy (FACIT) fa-
tigue scale (31), the Hospital Anxiety 
and Depression Scale (HADS) (32) 
were administered. Two of the initial 
31 patients recruited were excluded 
from the study for a proved OSA syn-
drome. As controls 29 age and sex 
matched healthy controls (HC) were 
recruited as well. To both patients and 
controls, the Pittsburgh Sleep Qual-
ity Index (PSQI) validated in Italian 
language (33), was administered after 
proper explanation. 
The PSQI (34) is the most commonly 
used retrospective self-report question-
naire that measures sleep quality over 
the previous month. It consists of 19 
questions grouped in 7 components 
(sleep quality, sleep latency, sleep dura-
tion, habitual sleep efficiency, sleep dis-
turbances, use of sleeping medications, 
and daytime dysfunction), each weight-
ed on a 0–3 scale, that are summed in a 
global PSQI score that ranges from 0 to 
21 with a higher score indicating worse 
sleep quality. A result equal to 5 or 
above is considered indicative of poor 
sleep quality. The seven components 
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above reported can be grouped accord-
ing to 3 main factors that synthesise 
sleep quality: F1, perceived sleep qual-
ity; F2, sleep efficiency; F3 daily dis-
turbances. Basically in both the global 
and components scales, higher scores 
reflect greater  sleep complaints.
The SF-36 (35) is a generic health sta-
tus measure with a global score range 
of 0–100; better health status achieves 
higher scores. It consists of 36 items as-
sessing 8 domains: physical function-
ing, bodily pain, role limitations due 
to physical health problems, general 
health perceptions, mental health, role 
limitations due to emotional problems, 
vitality, social functioning. The eight 
scales can be clustered into a physical 
component and a mental component, 
and it should be taken into considera-
tion that lower scores indicate higher 
disability in each specific domain. 
The FACIT-Fatigue scale (36) is a self-
administered questionnaire that evalu-
ates fatigue and its influence on daily 
activities and function. It comprises 13 
items, each with a categorical response 
scale (0 = not at all; 4 = very much). A 
total score is the sum of the individual 
items and ranges between 0 (maximum 
fatigue) and 52 (no fatigue) with scores 
≤32 reflecting severe fatigue. This scale 
has already been used in primary SS pa-
tients (3).
The HADS (37) is a self-report ques-
tionnaire divided into 2 subscales, 
HADS-A (anxiety) and HADS-D (de-
pression), both with 7 questions and a 
score range from 0 (no depression or 
anxiety) to 21 (maximal depression or 
anxiety). For each subscale, a score of 
0-7 indicates  normality, 8-10 a border-
line case, ≥11 a  probable clinically sig-
nificant anxiety or depression (38).
Statistical analysis
PSQI scores (global, F1, F2 and F3) 
have  been compared between pSS pa-
tients and HC by means of the Student 
t-test.
A subsequent analysis of correlation 
has been carried out on pSS between 
PSQI scores (global, F1, F2 and F3) 
and scores of ESSDAI, SSDAI, SSDDI, 
HADS-Anxiety, HADS-Depression, 
FACIT, SF36, measure of sialometry 
and of duration of disease.
Results 
Patients’ clinical and laboratory data 
are summarised in Table I. No statisti-
cally significant difference was found 
for age between cases (55.58±11.95) 
and HC (55.67±12.07).
Results on sleep quality differences 
between cases and HC are summa-
rised in Table II. Patients with pSS 
had a significantly higher mean PSQI 
global score (8.62±4.58) compared to 
HC (5.59±2.24; t=3.21, p=0.002) (Fig. 
1). In the patient’s group, 24 out of 29 
showed sleep complaints (82.76%) 
while the percentage appeared slightly 
reduced in the HC group (69%; 20 out 
of 29). All  3 factors of the PSQI-  per-
ceived sleep quality (F1), sleep efficien-
cy (F2) and the daily disturbances (F3)- 
reached a  higher value in cases than 
in HC (p=0.01, p=0.05 and p=0.009, 
respectively) (Fig. 2). 
Sixteen (55.2%) and 9 patients (31%) 
could be considered anxious or de-
pressed, respectively. The mean anxi-
ety HADS score was borderline in pSS 
patients (10.4±5.7), while the mean de-
pression HADS score was at the higher 
limit of normal values (7.4±4.1). No 
significant correlation between anxi-
ety/depression HADS and PSQI global 
score was found.
The FACIT fatigue scale was altered 
(mean values of  35.06±7.14), but there 
was no significant correlation with 
PSQI global scores. 
Significant negative correlations were 
found between global PSQI score and 
SF-36 subscales of both physical and 
mental domains, such as physical ac-
Table I. clinical and laboratory features.
Disease characteristics Total sample (n=29)
Age, mean (SD), years 55.89 (12.15)
Disease duration, mean (SD), months 43.14 (47.36)
Xerophtalmia, n (%) 26 (89.6 %)
Xerostomia, n (%) 25 (86.2%)
Pathological Schirmer’s testa, n (%) 20 (68.9 %)
Pathological non stimulated Sialometryb, n (%) 16 (55.2%)
Joint painc, n (%) 26 (89.6%)
ESSDAI, mean (SD) 4.45 (4.35)
SSDAI, mean (SD) 2.14 (1.87)
SSDDI, mean (SD) 1.48 (0.95) 
ANA, n (%) 25 (86.2%)
SSA and/or SSB, n (%) 17 (58.6%)
Pathological minor salivary glands biopsyd, n (%) 12 (92.3%)
Fibromyalgiae, n (%) 2 (6.9%)
Sleep disturbance (PSQI >5), n (%) 24 (82.7%)
Physical scoreSF36, mean (SD) 47.88 (21.54)
Mental score SF36 , mean (SD) 45.68 (20.51)
HADS anxiety score, mean (SD) 10.44 (5.77)
HADS depression score, mean (SD) 7.41 (4.09)
FACIT , mean (SD) 35.06 (7.13)
aless than 5 mm in 5 minutes; bless than 1.5 ml in 15 minutes; cWith or without joint inflammation; 
dNumber of focus (50 cells/4mm2) ≥1; eACR criteria (Wolfe F. et al. The American College of Rheu-
matology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. 
Arthritis Care Res 2010; 62: 600-10).
Table II. Sleep quality differences between pSS and HC.
Variable pSS patients Controls t p-value
 (mean±SD) (mean±SD) (df 56) 
PSQI globala 8.62 ± 4.58 5.59 ± 2.24 3.21 0.002
F1b 2.69 ± 2.30 1.38 ± 1.35 2.65 0.01
F2c 3.17 ± 2.22 2.24 ± 1.24 1.97 0.05
F3d 2.76 ± 1.33 1.97 ± 0.87 2.69 0.009
   
aPittsburgh Sleep Quality Index global score; bFactor F1: perceived sleep quality; cFactor F2: sleep 
efficiency; dFactor F3: daily disturbance.
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tivity (r=-0.63; p=0.0002), physical 
limitation (r=-0.49; p=0.007), physical 
pain (r=-0.43; p=0.02), vitality (r=-
0.45; p=0.01), social activity (r=-0.47; 
p=0.01), emotional limitation (r=-0.40; 
p=0.03) and mental health (r=-0.42; 
p=0.02). No other significant correla-
tion between PSQI global score and 
clinical variables emerged, in particu-
lar between PSQI and ESSDAI, SS-
DAI, SSDDI and disease duration. No 
difference was observed between SSA 
and/or SSB positive patients and nega-
tive ones, nor between untreated and 
treated patients independently from the 
drug (steroids, hydroxychloroquine or 
immunosuppressants). 
A similar correlational analysis was 
carried out with PSQI factors. The 
factor of perceived sleep quality (F1) 
showed only a negative correlation 
with the mental health subscale of 
emotional limitation (r=-0.38; p=0.04). 
On the other hand, F2 (sleep efficiency) 
positively correlated with anxiety as as-
sessed by HADS (r=0.46; p=0.01), and 
negatively correlated with SF-36 phys-
ical activity (r=-0.48; p=0.008) and 
pain (r=-0.40; p=0.03). Moreover, F2 
also negatively correlated with social 
activity (r=-0.39; p=0.04), and mental 
health (r=-0.37; p=0.05). Finally, with 
respect to factor F3 (daily disturbanc-
es) a more complex picture emerged: 
the PSQI factor positively correlated 
with anxiety (r=0.50; p=0.005) and de-
pression (r=0.44; p=0.01) as assessed 
by HADS, while a negative correla-
tion was observed with fatigue scale 
of FACIT (r=0.46; p=0.01). A nega-
tive correlation was instead observed 
with some subscales of SF-36, such as 
physical activity (r=0.78; p=0.000001), 
physical limitation (r=-0.54; p=0.003), 
physical pain (r=-0.53; p=0.003), gen-
eral health (r=-0.48; p=0.009), vitality 
(r=-0.75; p=0.000002), social activity 
(r=-0.62; p=0.0003), and mental health 
(r=-0.44; p=0.01). 
No other significant correlation be-
tween PSQI factors and clinical vari-
ables resulted statistically significant. 
Discussion   
Patients with pSS present a higher prob-
ability of sleep troubles with respect 
to matched controls. They showed a 
significant decrease of global sleep 
quality (as assessed by global score) 
and this was reflected also by signifi-
cant changes in perceived sleep qual-
ity, daily disturbances and, to less ex-
tent, in sleep efficiency. Correlational 
analysis showed that  bad sleep quality 
is usually linked to low levels in both 
physical and mental health subscales, 
i.e. higher disability. This relationship 
is mainly explained by the amount and 
intensity of daily disturbances, a sleep 
quality factor that positively correlates 
also with mood disturbances of pSS 
patients. 
People spend one third of their life-
time sleeping. A satisfying sleep qual-
ity is a requisite for a fine health status 
and vice versa a physical or mental 
disease may influence overall sleep 
quality. Sleep-wake disturbances have 
been described in patients with chronic 
disorders such as cancer (39), chronic 
fatigue syndromes (40) or generalised 
pain (41) and can affect the quality of 
life. However, the quality of sleep is 
generally neglected by both health care 
professionals, who do not routinely 
assess it in clinical practice (42), and 
patients themselves (43). This is par-
ticularly true in rheumatology, in fact, 
as far as we know, very few studies 
have evaluated the quality of sleep in 
patients with autoimmune diseases of 
rheumatological interest (24-28, 44, 
45) and this topic has been the subject 
of an interesting review (46).
Using a standardised sleep question-
naire, Gudbjörnsson et al. (1) first reg-
istered a significantly higher sleep defi-
Fig. 1. PSQI global score differences between pSS and HC.
PSQI: Pittsburgh Sleep Quality Index global score (*p-value = 0.002).
Fig. 2. PSQI Factors differences between pSS and HC. 
Factor F1, perceived sleep quality (*p-value =0.01); Factor F2, sleep efficiency (*p-value =0.05); 
Factor F3, daily disturbance (*p-value =0.009).
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cit (difference between need of sleep 
and actual sleeping time) in patients 
with pSS compared to healthy matched 
controls and subjects with Rheumatoid 
Arthritis, possibly caused by muscu-
lar tension, restless legs syndrome, or 
nocturnal pain. Actually, joint pain has 
been linked to poorer quantity/quality 
of sleep in pSS patients (9) and human 
and animal experimental research stud-
ies show a bidirectional relationship of 
disordered sleep to pain and fatigue. 
Even if fatigue, occasionally linked 
to a concomitant fibromyalgia (6), is 
a very common feature in pSS with a 
great impact on the quality of life (47), 
we could not demonstrate any corre-
lation between fatigue and sleep dis-
orders. This negative observation has 
been previously reported by Usmani 
and colleagues (10) who did not find 
any significant link between measures 
of sleep disruption, sleep apnea severi-
ty, and FACIT-F scores in pSS patients. 
It is plausible that fatigue in pSS may 
arise from different factors including 
fibromyalgia (4-6, 40), cytokine dise-
quilibrium (48, 49), autonomic nervous 
system disturbances (50), anxiety and 
depression (51-53), reduced aerobic 
capacity (54), and sub-clinical myosi-
tis (55). Sleep abnormalities as a possi-
ble cause of fatigue in pSS needs to be 
further evaluated, hopefully looking at 
both sleep micro- and macrostructure 
typical of these patients. 
The relationship between sleep and 
pain is even more complex: sleep depri-
vation is suspected to play a role in the 
onset and flares of some rheumatologic 
diseases but, as far as we know, only 
animal models support this hypothesis 
(56). In humans, sleep abnormalities 
can induce a hyperalgesic state (57) and 
modulate pain, and vice versa pain may 
negatively affect sleep, so that a vicious 
cycle of perpetuation and augmentation 
could arise. Wide spread pain is very 
common in patients with pSS (58). The 
result of this study seems to confirm the 
link between pain and sleep troubles 
as the higher the pain as estimated by 
SF36, the lower the quality of sleep.  
Dryness and the consequent necessity 
to frequently awake to sip water is an-
other possible reason for sleep depriva-
tion and daytime fatigue (9). Consider-
ing that strong relationships between 
mouth drying, increased surface ten-
sion of upper airway lining fluid, and 
increased airway collapsibility and ob-
structive sleep apneas have been dem-
onstrated (59), the increased airway 
drying is a likely explanation for the in-
creased prevalence of OSA in pSS (10). 
As a matter of fact, 2 out of 31 consecu-
tive pSS patients (6.4%) consecutively 
recruited for this study have a demon-
strated OSA syndrome, both of which 
are already using continuous positive 
airway pressure devices at night.   
Mood disorders, frequently reported 
in pSS patients (60), have been also 
associated to sleep disturbances (61, 
62). Anxiety disorders are associated 
with all PSQI subscales except use of 
medications for sleep (63) and in older 
subjects symptoms of short sleep du-
ration, daytime sleepiness and sleep 
disturbances are independently related 
to anxiety (64). Several studies sug-
gest that insomnia, chronic pain, and 
depression frequently overlap and are 
mutually interacting conditions with 
still unclear underlying mechanisms 
(65). Other epidemiological evidence 
suggests that the link between insomnia 
and depression is bidirectional. It is es-
timated that about 20% of patients with 
insomnia show some depressive symp-
toms whereas depression and depres-
sive symptoms seem to be the most im-
portant risk factors for insomnia (66).
In the present study, a high percentage 
of cases exhibit a clinical significant 
anxiety and/or depression, both associ-
ated with daily disorders but not with 
abnormalities in the perceived quality 
of sleep. Actually, it’s rather difficult 
to establish what comes first between 
mood disorders and sleep disturbances. 
A powerful and original aspect of 
our study is that it is the first one in 
which sleep quality in pSS was corre-
lated with disease activity and damage 
demonstrating that sleep disturbances 
are independent from these variables. 
Moreover, neither correlation was 
found between reduced quality of sleep 
and immunological profile (i.e the 
presence of autoantibodies) and nor 
with treatment. 
This study also has some limitations: 
the first is its relatively small sample 
size. Despite this, statistically signifi-
cant differences were observed in the 
prevalence of sleep disturbances be-
tween patients and controls. Secondar-
ily, an overall neuropsychological test-
ing would have been strengthened the 
study by assessing possible cognitive 
and behavioural effects of sleep quality 
decrease in pSS patients.
Future studies will better clarify the 
strong relationship between pSS and 
sleep also from a quantitative point of 
view: in this vein, an overnight poli-
somnography could add interesting 
information about micro- and macro-
structure of sleep, sleep temporal dy-
namics, as well as regarding possible 
differential effect on power spectra of 
slow-wave activity, the best marker of 
sleep homeostasis. 
In summary, sleep disturbances, fa-
tigue and mood disorders, are associ-
ated with pSS and more extensive re-
search is needed to better evaluate their 
intertwined relationship and determine 
whether interventions addressing these 
co-morbidities will help the underlying 
disease process and improve patients’ 
quality of life.
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